Design, synthesis, and molecular docking studies of benzimidazole-1,3,4-triazole hybrids as carbonic anhydrase I and II inhibitors

Basit Öğe Kaydı
dc.authoridcelik, ismail/0000-0002-8146-1663
dc.contributor.authorCelik, Ismail
dc.contributor.authorCevik, Ulviye Acar
dc.contributor.authorKucukoglu, Kaan
dc.contributor.authorNadaroglu, Hayrunnisa
dc.contributor.authorBostanci, Hayrani Eren
dc.contributor.authorIsik, Aysen
dc.contributor.authorOzkay, Yusuf
dc.date.accessioned2024-10-26T18:10:55Z
dc.date.available2024-10-26T18:10:55Z
dc.date.issued2024
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractn this study, with an aim to develop novel heterocyclic hybrids as potent enzyme inhibitors, we synthesized a series of 10 novel 2-(4-(4-ethyl-5-(2-(substitutedphenyl)-2-oxo-ethylthio)-4H-1,2,4-triazol-3-yl)-phenyl)-5,6-dimethyl-1H-benzimidazole (5a-5j) derivatives and characterized by H-1-NMR, C-13-NMR, and HRMS. These compounds were evaluated for their inhibitory activity against hCA I and hCA II. All the compounds exhibited good hCA I and hCA II inhibitory activities with IC50 values in range of 1.288 mu M-3.122 mu M. Among all these compounds, compound 5e, with an IC50 value of 1.288 mu M is the most active against carbonic hCA I. Compound 5h with an IC50 value of 1.532 mu M is the most active against carbonic hCA-II. Compounds 5a-5j were also evaluated for their cytotoxic effects on the L929 mouse fibroblast (normal) cell line. The compounds were also analyzed for their antioxidant capacity by TAS, FRAP, and DPPH activity. Enzyme inhibition kinetics showed all compounds 5a-5j to inhibit the enzyme by non-competitive. The most active compound 5e for hCA I and compound 5h for hCA-II were subjected to molecular docking, which revealed their binding interactions with the enzyme's active site, confirming the experimental findings.
dc.description.sponsorshipThe authors have nothing to report.
dc.description.sponsorshipThe authors have nothing to report.
dc.identifier.doi10.1111/cbdd.14351
dc.identifier.issn1747-0277
dc.identifier.issn1747-0285
dc.identifier.issue1
dc.identifier.pmid37697918
dc.identifier.scopus2-s2.0-85170707517
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1111/cbdd.14351
dc.identifier.urihttps://hdl.handle.net/20.500.12418/30443
dc.identifier.volume103
dc.identifier.wosWOS:001065797400001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofChemical Biology & Drug Design
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subject1,3,4-triazole
dc.subjectantioxidant
dc.subjectbenzimidazole
dc.subjectcarbonic anhydrase
dc.subjectmolecular docking
dc.titleDesign, synthesis, and molecular docking studies of benzimidazole-1,3,4-triazole hybrids as carbonic anhydrase I and II inhibitors
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu